[go: up one dir, main page]

PE20020351A1 - Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2 - Google Patents

Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2

Info

Publication number
PE20020351A1
PE20020351A1 PE2001000900A PE2001000900A PE20020351A1 PE 20020351 A1 PE20020351 A1 PE 20020351A1 PE 2001000900 A PE2001000900 A PE 2001000900A PE 2001000900 A PE2001000900 A PE 2001000900A PE 20020351 A1 PE20020351 A1 PE 20020351A1
Authority
PE
Peru
Prior art keywords
chloro
methyl
fluoroaniline
phenylacetic acid
cyclooxygenase
Prior art date
Application number
PE2001000900A
Other languages
English (en)
Inventor
Simon David Bateman
Alberto Gimona
Jurij Holinej
Jasper Huels
Sumedha Jayawardene
Victor Sloan
Anees Abdulquadar Karnachi
Maha Y Khaled
Richard Macerata
Lochlainn Eimear Mairin Nic
Argeris Jerry Karabelas
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20020351A1 publication Critical patent/PE20020351A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DE 60% A 90% POR PESO DE ACIDO 5-METIL-2-(2'-CLORO-6'-FLUOROANILINO)FENILACETICO. LA COMPOSICION ADEMAS COMPRENDE ENTRE 50mg Y 1200mg DE DICHO ACIDO O UNA SAL FARMACEUTICAMENTE ACEPTABLE JUNTO A CELULOSA MICROCRISTALINA, MONOHIDRATO DE LACTOSA, CROSCARMELOSA DE SODIO, POVIDONA, DIOXIDO DE TITANIO, ESTEARATO DE MAGNESIO. SE REFIERE TAMBIEN A UNA COMPOSICION QUE COMPRENDE UNA CANTIDAD EFECTIVA DE ACIDO 5-METIL-2-(2'-CLORO-6'-FLUOROANILINO)FENILACETICO Y DE 0.01% A 2% EN PESO DE ALCOHOL 5-METIL-2-(2'-CLORO-6'-FLUOROANILINO)BENCILICO. LA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE UN DESORDEN O CONDICION DEPENDIENTE DE LA CICLOOXIGENASA-2
PE2001000900A 2000-09-11 2001-09-07 Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2 PE20020351A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23165500P 2000-09-11 2000-09-11
US23226100P 2000-09-14 2000-09-14

Publications (1)

Publication Number Publication Date
PE20020351A1 true PE20020351A1 (es) 2002-06-14

Family

ID=26925315

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000900A PE20020351A1 (es) 2000-09-11 2001-09-07 Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2

Country Status (28)

Country Link
US (2) US20020061932A1 (es)
EP (1) EP1331972B1 (es)
JP (2) JP2004527458A (es)
KR (1) KR20030036730A (es)
CN (1) CN100490797C (es)
AR (1) AR030630A1 (es)
AT (1) ATE366128T1 (es)
AU (2) AU2002213900C1 (es)
BR (1) BR0113809A (es)
CA (1) CA2416771C (es)
CY (1) CY1107729T1 (es)
CZ (1) CZ2003673A3 (es)
DE (1) DE60129238T2 (es)
DK (1) DK1331972T3 (es)
ES (1) ES2290181T3 (es)
HU (1) HUP0301128A3 (es)
IL (2) IL154238A0 (es)
MX (1) MXPA03002105A (es)
MY (1) MY126117A (es)
NO (1) NO20031095L (es)
NZ (1) NZ524785A (es)
PE (1) PE20020351A1 (es)
PL (1) PL359721A1 (es)
PT (1) PT1331972E (es)
RU (1) RU2316324C2 (es)
SI (1) SI1331972T1 (es)
SK (1) SK2902003A3 (es)
WO (1) WO2002020090A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114527A1 (en) * 2001-08-31 2003-06-19 Karnachi Anees Abdulquadar Pharmaceutical composition
GB0201520D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Pharmaceutical uses
BR0308156A (pt) * 2002-03-07 2005-01-04 Novartis Ag Composições farmacêuticas sólidas contendo lumiracoxib
AU2003248642A1 (en) 2002-06-11 2003-12-22 Nitromed, Inc. Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
PE20040844A1 (es) 2002-11-26 2004-12-30 Novartis Ag Acidos fenilaceticos y derivados como inhibidores de la cox-2
TWI327913B (en) * 2003-03-12 2010-08-01 Novartis Ag Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid
US20050131028A1 (en) * 2003-09-11 2005-06-16 Pharmacia Corporation Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
RU2423979C2 (ru) * 2005-06-17 2011-07-20 АФТ Фармасьютикалз Лимитед Новая фармацевтическая композиция и ее применение в способе лечения пациентов с гиперемией и отеком слизистой оболочки верхних дыхательных путей
FR2898492B1 (fr) * 2006-03-15 2008-06-06 Pierre Fabre Medicament Sa Comprimes orodispersibles de domperidone
WO2008008120A1 (en) * 2006-07-14 2008-01-17 Fmc Corporation Solid form
US20080237823A1 (en) * 2007-01-11 2008-10-02 Analog Devices, Inc. Aluminum Based Bonding of Semiconductor Wafers
AU2009282901A1 (en) * 2008-08-22 2010-02-25 Novartis Ag Use of a COX-2 inhibitor for the treatment of a COX-2 dependent disorder in a patient not carrying HLA alleles associated with hepatotoxicity
WO2010056741A2 (en) 2008-11-12 2010-05-20 Auspex Pharmaceuticals, Inc. Phenylacetic acid inhibitors of cyclooxygenase
CN103773596B (zh) * 2013-12-31 2016-05-18 上海复力生物医药科技有限公司 磷虾油的制备方法
KR102557900B1 (ko) 2016-09-07 2023-07-19 트러스티즈 오브 터프츠 칼리지 면역-dash 억제제와 pge2 길항제를 이용한 병행 요법
US11730725B2 (en) 2017-09-26 2023-08-22 Tesaro, Inc. Niraparib formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0701449B1 (en) * 1993-06-08 2003-08-06 Novartis AG Process for the preparation of an oral solid dosage form containing diclofenac
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
CN1140267C (zh) * 1996-05-17 2004-03-03 麦克公司 治疗环加氧酶-2介导的疾病的每天一次的组合物
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
US20030114527A1 (en) * 2001-08-31 2003-06-19 Karnachi Anees Abdulquadar Pharmaceutical composition

Also Published As

Publication number Publication date
NO20031095D0 (no) 2003-03-10
EP1331972B1 (en) 2007-07-04
PT1331972E (pt) 2007-10-16
DE60129238T2 (de) 2008-03-06
AU2002213900C1 (en) 2006-07-27
CA2416771A1 (en) 2002-03-14
CN100490797C (zh) 2009-05-27
CY1107729T1 (el) 2013-04-18
WO2002020090A2 (en) 2002-03-14
JP2004527458A (ja) 2004-09-09
AU1390002A (en) 2002-03-22
EP1331972A2 (en) 2003-08-06
KR20030036730A (ko) 2003-05-09
US20040186179A1 (en) 2004-09-23
HUP0301128A3 (en) 2005-04-28
ES2290181T3 (es) 2008-02-16
RU2316324C2 (ru) 2008-02-10
MY126117A (en) 2006-09-29
CZ2003673A3 (cs) 2003-06-18
US20020061932A1 (en) 2002-05-23
WO2002020090A9 (en) 2003-10-30
BR0113809A (pt) 2003-07-29
DE60129238D1 (de) 2007-08-16
PL359721A1 (en) 2004-09-06
NO20031095L (no) 2003-03-10
AU2002213900B2 (en) 2006-02-16
SI1331972T1 (sl) 2007-12-31
CN1455691A (zh) 2003-11-12
WO2002020090A3 (en) 2003-05-30
AR030630A1 (es) 2003-08-27
SK2902003A3 (en) 2003-10-07
CA2416771C (en) 2010-11-02
NZ524785A (en) 2005-10-28
ATE366128T1 (de) 2007-07-15
DK1331972T3 (da) 2007-11-05
IL154238A (en) 2008-11-26
HUP0301128A2 (hu) 2003-10-28
MXPA03002105A (es) 2003-06-19
IL154238A0 (en) 2003-09-17
JP2011144194A (ja) 2011-07-28

Similar Documents

Publication Publication Date Title
PE20020351A1 (es) Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2
ES2244831T5 (es) Uso de pantenol y/o ácido pantoténico y ácido hialurónico y/o hialuronato para la producción de una composición farmacéutica para aplicación oftalmológica
PE20130210A1 (es) Composicion farmaceutica solida que comprende un derivado de bencimidazol y un agente de control de ph
BR9611015A (pt) Composto, composição farmacêutica e processo para o tratamento de uma doença inflamatória suscetìvel ao tratamento com um agente não-tóxico anti-inflamatório não-esteróide, sal farmaceuticamente aceitável, utilização de um composto
UY29919A1 (es) Derivados sustituidos de 3,4-dihidroisoquinolin-1-amino-trifluoroacetato, sus composiciones farmacéuticas y aplicaciones
EE05103B1 (et) Famatseutilised kompositsioonid, mis sisaldavad asetidiini derivaate, asetidiini derivaadid ja nende valmistamise meetodid
MA31706B1 (fr) Formulations galéniques de composés organiques
NZ584686A (en) Compositions of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate(S)-3'-methyl-2' -(pentanoyl{ 2 -(tetrazol-5-ylate)biphenyl-4'-ylmethyl} amino)butyrate]hemipentahydrate
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
NO20076595L (no) Behandling av leversykdommer hvor jern spiller en rolle i patogenesen
UY30274A1 (es) Derivados sustituidos de la n-(4-metil-1,3-tiazol-2-il)guanidina, formulaciones farmacéuticas conteniéndolo y aplicaciones
AR079404A1 (es) Antagonista dp2 y composicion farmaceutica, uso y proceso de preparacion
BR9913575A (pt) Composições compreendendo sais de amina simpatomimética inadequadas para uso ilegal
CO5560554A2 (es) Composicion farmaceutica que comprende lumiracoxib
SV1997000026A (es) Composiciones farmaceuticas para el tratamiento de la rinitis
AR051965A1 (es) Sales de la n-[2-( { (3r)-1-[trans-4-hidroxi-4-(6- metoxipiridin-3-il)-ciclohexil] pirrolidin-3- il} amino)-2- oxoetil]-3-(trifluormetil) benzamida
EP2005962A4 (en) THERAPEUTIC AGENT FOR INFLAMMATORY ABDOMINAL DISEASE
BRPI0413186A (pt) composição de fexofenadina e processo para preparação da mesma
MA32498B1 (fr) Compositions pharmaceutiques de rosuvastatine calcium
ES2191099T3 (es) Derivados de hidantoina como productos intermedios para principios activos farmaceuticos.
DK2069334T3 (da) Aspalathin-lignende dihydrochalcon, ekstrakter af ufermenteret rooibos og fremgangsmåde til fremstilling
AR044014A1 (es) Composiciones farmaceuticas para administracion intranasal de acido [2-(8,9-dioxo-2, 6-diazabiciclo [5.2.0) non-1 (7) -en-2-il)alquil]-fosfonico y derivados y metodos de utilizacion de las mismas
CL2003002588A1 (es) Uso de una composicion farmaceutica que comprende acido n,n-dimetoximetildifenil barbiturico, acido n-metoximetildifenil barbiturico o acido difenil barbiturico o una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el t
AR118131A1 (es) Composición farmacéutica que comprende compuesto derivado de benzoimidazol
BR9917315A (pt) Composições medicinais para liberação imediata para uso oral

Legal Events

Date Code Title Description
FC Refusal